Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin

被引:3
|
作者
Meconi, Federico [1 ]
Secchi, Roberto [1 ]
Palmieri, Raffaele [1 ]
Vaccarini, Sara [1 ]
Rapisarda, Vito Mario [1 ]
Gianni, Laura [1 ]
Esposito, Fabiana [1 ]
Provenzano, Ida [1 ]
Nasso, Daniela [1 ]
Pupo, Livio [1 ]
Cantonetti, Maria [1 ]
机构
[1] Univ Tor Vergata, Dept Biomed & Prevent, Haematol Div, Viale Oxford 81, Rome, Italy
关键词
LYMPHOPROLIFERATIVE DISORDERS; GUIDELINES; EORTC; HEAD;
D O I
10.1155/2019/9651207
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary cutaneous anaplastic large cell lymphoma is a CD-30 positive lymphoproliferative disorder with good prognosis, usually treated with radiation therapy and surgery. Head, neck, and extremities are the most frequently involved sites. In this paper, we describe an unusual case of oral localization, recurring after skin-involving radiotherapy, successfully treated with sixteen cycles of brentuximab vedotin. This could be a more effective approach with a less detrimental toll for treating these rare disorders.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report
    Arroyo-Andres, Jorge
    Agud-Dios, Manuel
    Rubio-Muniz, Carmen A.
    Vico-Alonso, Cristina
    Cortijo-Cascajares, Susana
    Ortiz-Romero, Pablo L.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (07) : E267 - E269
  • [2] Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin
    Sasapu, Appalanaidu
    Dunn, Andrew L. J.
    Gardner, Jerad
    Wong, Henry K.
    BMJ CASE REPORTS, 2021, 14 (07)
  • [3] Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
    Onaka, Takashi
    Kitagawa, Tomoya
    Kawakami, Chika
    Yonezawa, Akihito
    TURKISH JOURNAL OF HEMATOLOGY, 2018, 35 (02) : 135 - 136
  • [4] Brentuximab vedotin in anaplastic large cell lymphoma
    Skarbnik, Alan P. Z.
    Smith, Mitchell R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 633 - 639
  • [5] Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin
    Amrita Desai
    Gladys H. Telang
    Adam J. Olszewski
    Annals of Hematology, 2013, 92 : 567 - 568
  • [6] Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin
    Desai, Amrita
    Telang, Gladys H.
    Olszewski, Adam J.
    ANNALS OF HEMATOLOGY, 2013, 92 (04) : 567 - 568
  • [7] Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
    Sahin, Mustafa
    Miskioglu, Mine
    Inanir, Isil
    Akar, Hikmet
    Nese, Nalan
    Temiz, Peyker
    Aydogdu, Ismet
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (01) : 85 - 87
  • [8] Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin
    Milan, Elisa
    Miceli, Paola
    Sernicola, Alvise
    Finotto, Silvia
    Marino, Dario
    Alaibac, Mauro
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (06)
  • [9] Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
    Burgstaller S.
    Thaler J.
    memo - Magazine of European Medical Oncology, 2017, 10 (3) : 170 - 172
  • [10] Brentuximab Vedotin in primary cutaneous CD30+large-cell anaplastic T-Cell Lymphoma
    Moritz, R. K. C.
    Patsinakidis, N.
    Terras, S.
    Moellenhoff, K.
    Gambichler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 921 - 921